Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12911161 | 0.90 | TSHR (0.69) | TSHRGLANPC1RAB9APARP10 | |
| SCHEMBL19829316 | 0.89 | TSHR (0.67) | TSHRGLANPC1RAB9APOLB | |
| SCHEMBL16309014 | 0.88 | TSHR (0.58) | TSHRGLANPC1RAB9APOLB | |
| SCHEMBL14409571 | 0.87 | TSHR (0.70) | TSHRGLANPC1RAB9APOLB | |
| SCHEMBL12569718 | 0.85 | TSHR (0.68) | TSHRGLANPC1RAB9APOLB | |
| SCHEMBL7610899 | 0.82 | GLA (0.61) | TSHRGLANPC1RAB9APOLB | |
| SCHEMBL19831807 | 0.82 | TSHR (0.58) | TSHRGLANPC1RAB9APOLB | |
| SCHEMBL314589 | 0.80 | TSHR (0.75) | TSHRGLARAB9AMAPTGAA | |
| SCHEMBL3339277 | 0.80 | TSHR (0.67) | TSHRGLANPC1POLBGAA | |
| SCHEMBL4172039 | 0.80 | TSHR (0.67) | TSHRGLANPC1POLBPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034869-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180028511-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034869-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | TSHR 659/4885GLA 3374/4885NPC1 174/4885 |
| US-20180028511-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | TSHR 521/4885GLA 3222/4885NPC1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.